Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Chronic Hepatitis C Clinical Trial

Official title:
A Phase I/II, Open Clinical Trial to Assess the Safety, Tolerability and Efficacy of a Fixed Dose Combination Therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN Alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected Subjects Who Failed to Respond Following a Course of Peg-IFN and RBV Therapy (SoC).

Status Not yet recruiting

Clinical Trial Summary

The study is aimed to investigate the safety, tolerability and efficacy of a fixed dose combination therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (PEG-IFN alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected adult subjects who failed to respond following a course of PEG-IFN and RBV Therapy.

Clinical Trial Description

This is a phase I/II, open clinical trial to assess the safety, tolerability and preliminary efficacy data of a fixed dose combination therapy of: HCQ, Peg-IFN alpha-2a and RBV in chronic hepatitis C genotype 1 infected subjects who failed to respond following a course of Peg-IFN and RBV Therapy (SoC). The study is a single center trial to be conducted at the Department of Gastroenterology & Hepatology, at Sheba Medical Center, Tel Hashomer, Israel.

Overall, thirty six (36) patients will be recruited. All patients enrolled will have a documented history of chronic HCV disease and being non-responder on earlier Peg-IFN based treatment lasting for at least 12 consecutive weeks prior to study enrolment.

The expected duration of patient screening period prior to enrollment into this study is in-between six weeks (42 days) up to 2 days prior to the study enrollment day at visit 2 (verification of compliance with inclusion/exclusion criteria including clinical laboratory results). Eligible patients will be enrolled into the study and will be observed twice on the first week of the study, once a week during the initiation of the treatment period at weeks 2,3 and week 4, later during the treatment period once a month at weeks 8-48 and at two follow up visits post treatment to take place at week 60 and 72 (allowing a time window of ± 5 days for all visits). ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01272310
Study type	Interventional
Source	Sheba Medical Center
Contact	Yaakov Maor, Dr
Phone	97235302906
Email	yaakov.maor@sheba.health.gov.il
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	January 2011
Completion date	July 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01937975` - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)	Phase 1
Completed	`NCT03673696` - The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects	Phase 1
Completed	`NCT02250001` - Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C	N/A
Completed	`NCT03088917` - 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Completed	`NCT02207088` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease	Phase 3
Not yet recruiting	`NCT02865369` - Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment	N/A
Recruiting	`NCT02638233` - Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy	Phase 4
Not yet recruiting	`NCT02511496` - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia	N/A
Not yet recruiting	`NCT01949168` - A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV	Phase 2
Completed	`NCT02788682` - Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy	N/A
Completed	`NCT01439776` - Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients	Phase 4
Recruiting	`NCT01360879` - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease	N/A
Recruiting	`NCT01360892` - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography	N/A
Completed	`NCT00968357` - Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed	Phase 2
Terminated	`NCT00962936` - Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection	Phase 1/Phase 2
Recruiting	`NCT00575627` - Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels	Phase 4
Recruiting	`NCT01178749` - Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments	N/A
Completed	`NCT00537407` - A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment	Phase 2
Recruiting	`NCT00370617` - Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	Phase 4
Completed	`NCT01684787` - Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients	Phase 4